Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model

Journal of Medical Virology

Volumn 89, Issue 5, 2017, Pages 759-766

  Don, Еlena S ^a   Emelyanova, Alexandra G ^a   Yakovleva, Natalia N ^b   Petrova, Nataliia V ^a   Nikiforova, Marina V ^b   Gorbunov, Evgeniy A ^b   Tarasov, Sergey А ^b   Morozov, Sergey G ^a   Epstein, Оleg I ^a  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^b OOO NPF Materia Medica Holding   (Russian Federation)

Author keywords

animal models of infection; antibody containing preparations; antiviral agents; influenza virus

Indexed keywords

ANAFERON; ANTIVIRUS AGENT; OSELTAMIVIR; UNCLASSIFIED DRUG; ANTIBODY; IMMUNOLOGIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EMBRYO; FEMALE; INFLUENZA A (H1N1); INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS/CALIFORNIA/07/09 (H1N1); LIFESPAN; LOBAR PNEUMONIA; MOUSE; NONHUMAN; SURVIVAL RATE; SYMPTOM; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; IMMUNOLOGY; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; PNEUMONIA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85001759518     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24717     Document Type: Article

References (44)

1. Bruder D, Srikiatkhachorn A, Enelow RI. 2006. Cellular immunity and lung injury in respiratory virus infection. Viral Immunol 19:147–155.
2. Cottey R, Rowe CA, Bender BS. 2001. Influenza virus. Curr Protoc Immunol 42:19.11.1–19.11.32.
3. Dong G, Peng C, Luo J, Wang C, Han L, Wu B, Ji G, He H. 2015. Adamantane-resistant influenza A viruses in the world (1902–2013): Frequency and distribution of M2 gene mutations. PLoS ONE 10:e0119115.
4. Epstein OI. 2009. Ultralow doses (history of one research). Moscow: RAMS Publishing House, p 336.
5. Epstein OI. 2013. The phenomenon of release activity and the hypothesis of “spatial” homeostasis. Usp Fiziol Nauk 44:54–76.
6. Gavrilova E, Gorbunov E, Borshcheva A, Guryanova N, Tarasov S. 2014a. Application of drugs based on release-active antibodies as immunotherapy agents. J Clin Cell Immunol 5:62.
7. Gavrilova ES, Bobrovnik SA, Sherriff G, Myslivets AA, Tarasov SA, Epstein OI. 2014b. Novel approach to activity evaluation for release-active forms of anti-interferon-gamma antibodies based on enzyme-linked immunoassay. PLoS ONE 9:e97017.
8. Gavrilova ES, Tarasov SA. 2014. Modern approaches for the investigation of natural autoantibodies to cytokine by various immunoassays. Immunologiya 35:107–112.
9. Gorbunov EA, Ertuzun IA, Kachaeva EV, Tarasov SA, Epstein OI. 2015. In vitro screening of major neurotransmitter systems possibly involved in the mechanism of action of antibodies to S100 protein in released-active form. Neuropsychiatr Dis Treat 11:2837–2846.
10. Guide for the Care and Use of Laboratory Animals. 1996. 7th edition. Washington D.C.: National Academy Press. p 125.
11. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. 2009. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08. Emerg Infect Dis 15:155–162.
12. Hurt AC. 2014. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol 8:22–29.
13. ICH E.W.G. 1994. Guideline for industry. Dose-response information to support drug registration. ICH-E41994.1994. Rockville: CDER. p 15.
14. Khoufache K, LeBouder F, Morello E, Laurent F, Riffault S, Andrade-Gordon P, Boullier S, Rousset P, Vergnolle N, Riteau B. 2009. Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-gamma-dependent pathway. J Immunol 182:7795–7802.
15. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. 2010. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol 8:e1000412.
16. Killip MJ, Fodor E, Randall RE. 2015. Influenza virus activation of the interferon system. Virus Res 209:11–22.
17. Kong W, Wang F, Dong B, Ou C, Meng D, Liu J, Fan ZC. 2015. Novel reassortant influenza viruses between pandemic (H1N1) 2009 and other influenza viruses pose a risk to public health. Microb Pathog 89:62–72.
18. Krammer F, Palese P. 2015. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 14:167–182.
19. Kudin MV, Tarasov SA, Kachanova MV, Skripkin AV, Fedorov YN. 2009. Anaferon (pediatric formulation) in prophylactics of acute respiratory viral infection in children. Bull Exp Biol Med 148:279–282.
20. Lamb RA, Roberts KL. 2014. In: Influenza (MS 654). Chapter 02606, Caplan MJ, editor. Reference Module in Biomedical Research. Amsterdam: Elsevier Inc.
21. Martyushev-Poklad AV, Kotelnikova MP, Uchaikin VF, Dugina JL, Epstein OI, Sergeeva SA. 2004. A novel antiviral based on oral antibodies: Clinical benefits in paediatric upper respiratory infections. Clin Microbiol Infect 10:125–126.
22. Moorthy NS, Poongavanam V, Pratheepa V. 2014. Viral M2 ion channel protein: A promising target for anti-influenza drug discovery. Mini Rev Med Chem 14:819–830.
23. Narasaraju T, Sim MK, Ng HH, Phoon MC, Shanker N, Lal SK, Chow VT. 2009. Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: Insights into viral virulence, tissue tropism and host pathogenesis. Microbes Infect 11:2–11.
24. Nguyen-Van-Tam JS, Venkatesan S, Muthuri SG, Myles PR. 2015. Neuraminidase inhibitors: Who, when, where? Clin Microbiol Infect 21:222–225.
25. Obraztsova EV, Osidak LV, Golovacheva EG, Afanas'eva OI, Mil'kint KK, Koroleva EG, Drinevskii VP, Vasil'eva IA. 2009. Interferon status in children during acute respiratory infections. Therapy with interferon. Bull Exp Biol Med 148:275–278.
26. Oh DY, Hurt AC. 2014. A review of the antiviral susceptibility of human and avian influenza viruses over the last decade. Scientifica (Cairo) 2014:430629.
27. Peteranderl C, Herold S, Schmoldt C. 2016. Human influenza virus infections. Semin Respir Crit Care Med 37:487–500.
28. Prabhu N, Ho AW, Wong KH, Hutchinson PE, Chua YL, Kandasamy M, Lee DC, Sivasankar B, Kemeny DM. 2013. Gamma interferon regulates contraction of the influenza virus-specific CD8 T cell response and limits the size of the memory population. J Virol 87:12510–12522.
29. Pschenitza M, Gavrilova ES, Tarasov SA, Knopp D, Niessner R, Epstein OI. 2014. Application of a heterogeneous immunoassay for the quality control testing of release-active forms of diclofenac. Int Immunopharmacol 21:225–230.
30. Reed LJ. 1938. A simple method of estimating fifty percent endpoints. Am J Hyg 27:493–497.
31. Reeves PT, Roesch C, Raghnaill MN. 2015. In: Drug action and pharmacodynamics. Reeves PT, Roesch C, Raghnaill MN, editors. Merck Manual. Vol. 2015. Merck, http://www.merckvetmanual.com/mvm/pharmacology/pharmacology_introduction/drug_action_and_pharmacodynamics.html
32. Sergeev AN, P'Iankov OV, Shishkina LN, Duben LG, Petrishchenko VA, Zhukov VA, P'Iankova OG, Sviatchenko LI, Sherstoboev E, Karimova TV, Martiushev-Poklad AV, Sergeeva SA, Epshtein OI, Glotov AG, Glotova TI. 2004. Antiviral activity of oral ultralow doses of antibodies to gamma-interferon: Experimental study of influenza infection in mice. Antibiot Khimioter 49:7–11.
33. Sharp PM. 2002. Origins of human virus diversity. Cell 108:305–312.
34. Sherstoboev EY, Masnaya NM, Churin AA, Borsuk OS, Martyushev AV, Sergeeva SA, Epstein OI, Dygai AM, Goldberg ED. 2003. Immunotropic effects of potentiated antibodies to human interferon-gamma. Bull Exp Biol Med 135:70–72.
35. Shishkina LN, Sergeev AN, Kabanov AS, Skarnovich MO, Evtin NK, Mazurkova NA, Sergeev AA, Belopolskaya MV, Kheyfets IA, Dugina JL, Tarasov SA, Sergeeva SA, Epstein OI. 2008. Study of efficiency of therapeutic and preventive anaferon (pediatric formulation) in mice with influenza infection. Bull Exp Biol Med 146:763–765.
36. Shishkina LN, Skarnovich MO, Kabanov AS, Sergeev AA, Olkin SE, Tarasov SA, Belopolskaya MV, Sergeeva SA, Epstein OI, Malkova EM, Stavsky EA, Drozdov IG. 2010. Antiviral activity of Anaferon (pediatric formulation) in mice infected with pandemic influenza virus A(H1N1/09). Bull Exp Biol Med 149:612–614.
37. Sidwell RW, Smee DF. 2004. Experimental disease models of influenza virus infections: Recent developments. Drug Discov Today Dis Models 1:57–63.
38. Susloparov MA, Makhova NM, Noskova NV, Pliasunov IV, Susloparov IM, Sergeev AN, Sherstoboev E, Martiushev-Poklad AV, Sergeeva SA, Epshtein OI, Glotov AG, Glotova TI. 2004. Efficacy of therapeutic and prophylactic actions of ultralow doses of antibodies to gamma-interferon in experimental murine model of herpes virus. Antibiot Khimioter 49:3–6.
39. Tarasov SA, Dugina JL. 2008. Oral antibody to interferon gamma in ultra low doses: Clinical efficacy and interferon stimulation in patients. 5th Congress of European Pharmacology Society. Vol. 22. Manchester, UK: Fundamental & Clinical Pharmacology, p 37.
40. Tarasov SA, Zarubaev VV, Gorbunov EA, Sergeeva SA, Epstein OI. 2012. Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice. Antiviral Res 93:219–224.
41. Vasil'ev AN, Sergeeva SA, Kachanova MV, Tarasov SA, Elfimova UV, Dugina JL, Epshtein OI. 2008. Use of ultralow doses of antibodies to gamma-interferon in the treatment and prophylaxis of viral infections. Antibiot Khimioter 53:32–35.
42. Waynforth DHB, Brain PP, Sharpe MT, Stewart MDF, Applebee MKA, Darke DPGG. 1998. Good Practice Guidelines. Administration of Substances (Rat, Mouse, Guinea Pig, Rabbit). In: Association, L.A.S. (Ed.), issue 1, PO Box 3993, Tamworth, Staffordshire, B78 3QU, p 4.
43. Wiley JA, Cerwenka A, Harkema JR, Dutton RW, Harmsen AG. 2001. Production of interferon-gamma by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology. Am J Pathol 158:119–130.
44. Zhavbert ES, IuL Dugina, Epshtein OI. 2013. Immunotropic properties of anaferon and anaferon pediatric. Antibiot Khimioter 58:17–23.